Article detail · 2023 · article
Efficacy and safety of 48 weeks of guselkumab for patients with Crohns disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Journal
Elsevier BV
The ISSN points to another catalog journal; the name is from the YÖKSİS record.
ISSN2468-1253
YÖKSİS
OpenAlex
Open access · green
Top 1%
Year2023
Citations73OpenAlex
Citations60Semantic Scholar · 4 influential
Percentile%99.3
FWCI14.281.00 = world average
Scopus (SJR)Q1
WoS (JCR)Q1
Data source split
- YÖKSİSYÖKSİS article record
- YÖKSİS venueElsevier BV
- Catalog match (ISSN)The Lancet Gastroenterology and Hepatology
- OpenAlexOpenAlex enrichment (abstract, citations, topics)
- Semantic Scholarcitation count (not merged with OpenAlex)
Abstract
Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
73citationsOpenAlex · cited_by_count (cache / database)
3 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- 2025 Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI StudyCitations 49 · OpenAlex
- 2026 Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialCitations 7 · OpenAlex
- 2026 Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trialCitations 3 · OpenAlex